MCID: HPT004
MIFTS: 44

Hepatic Coma

Categories: Liver diseases, Neuronal diseases

Aliases & Classifications for Hepatic Coma

MalaCards integrated aliases for Hepatic Coma:

Name: Hepatic Coma 12 55 15 73
Hepatic Encephalopathy 44 73
Hepatocerebral Intoxication 12

Classifications:



External Ids:

Disease Ontology 12 DOID:12550
ICD10 33 K72.91
MeSH 44 D006501
SNOMED-CT 68 72836002

Summaries for Hepatic Coma

MalaCards based summary : Hepatic Coma, also known as hepatic encephalopathy, is related to viral hepatitis and alcoholic liver cirrhosis. An important gene associated with Hepatic Coma is F2 (Coagulation Factor II, Thrombin), and among its related pathways/superpathways are Sterol Regulatory Element-Binding Proteins (SREBP) signalling and FOXA2 and FOXA3 transcription factor networks. The drugs Diphenhydramine and Promethazine have been mentioned in the context of this disorder. Affiliated tissues include liver, brain and testes, and related phenotype is normal.

Related Diseases for Hepatic Coma

Diseases related to Hepatic Coma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 164)
# Related Disease Score Top Affiliating Genes
1 viral hepatitis 32.5 ALB F2 GPT
2 alcoholic liver cirrhosis 32.2 ALB F2
3 hepatitis a 31.1 ALB F2 GPT
4 liver disease 30.2 ALB F2 GPT
5 liver cirrhosis 30.0 ALB F2 GPT
6 esophageal varix 29.9 ALB F2
7 infantile liver failure syndrome 1 29.9 ALB F2 GPT
8 peritonitis 29.9 ALB F2
9 hepatitis b 29.8 ALB F2 GPT
10 schistosomiasis 29.8 ALB F2
11 hepatorenal syndrome 29.7 ALB F2
12 acute liver failure 29.7 ALB F2 GPT TSPO
13 portal hypertension 29.6 ALB F2 GPT
14 autoimmune hepatitis 29.4 F2 GPT
15 alcoholic hepatitis 29.4 ALB F2 GPT
16 hepatic encephalopathy 29.4 ALB F2 GPT TSPO
17 congenital extrahepatic portosystemic shunt 11.3
18 hepatic veno-occlusive disease 11.0
19 carnitine palmitoyltransferase i deficiency , muscle 11.0
20 hepatitis 10.4
21 brain edema 10.2
22 helicobacter pylori infection 10.1
23 hepatoportal sclerosis 10.1 F2 GPT
24 hepatitis d 10.1 F2 GPT
25 nonalcoholic steatohepatitis 10.1 F2 GPT
26 antipyrine metabolism 10.1 ALB F2
27 non-a-e hepatitis 10.1 ALB F2
28 encephalopathy 10.1
29 epstein-barr virus hepatitis 10.1 ALB F2
30 fournier gangrene 10.0 ALB F2
31 abdominal tuberculosis 10.0 ALB F2
32 migraine with aura 10.0 F2 SCN1A
33 splenic disease 10.0 ALB F2
34 ascending cholangitis 10.0 ALB F2
35 hypersplenism 10.0 ALB F2
36 compartment syndrome 10.0 ALB F2
37 autoimmune disease of urogenital tract 10.0 ALB F2
38 hepatic vascular disease 10.0 ALB F2
39 pulmonary artery disease 10.0 ALB F2
40 dysfibrinogenemia 10.0 ALB F2
41 varicose veins 10.0
42 thrombosis 10.0
43 status epilepticus 10.0
44 vein disease 10.0 ALB F2
45 intermittent claudication 10.0 ALB F2
46 fascioliasis 10.0 ALB GPT
47 typhoid fever 10.0 ALB F2
48 dengue hemorrhagic fever 10.0 ALB F2
49 biliary tract disease 10.0 ALB F2
50 homocysteinemia 10.0 ALB F2

Graphical network of the top 20 diseases related to Hepatic Coma:



Diseases related to Hepatic Coma

Symptoms & Phenotypes for Hepatic Coma

MGI Mouse Phenotypes related to Hepatic Coma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 normal MP:0002873 9.02 ALB DBI F2 SCN1A TSPO

Drugs & Therapeutics for Hepatic Coma

Drugs for Hepatic Coma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 57)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Diphenhydramine Approved, Investigational Phase 4 147-24-0, 58-73-1 3100
2
Promethazine Approved, Investigational Phase 4 60-87-7 4927
3
Histamine Approved, Investigational Phase 4 51-45-6, 75614-87-8 774
4
Buprenorphine Approved, Illicit, Investigational, Vet_approved Phase 4 52485-79-7 40400 644073
5
Naloxone Approved, Vet_approved Phase 4 465-65-6 5284596
6
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
7
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 11103-57-4, 68-26-8 445354
8 Gastrointestinal Agents Phase 4,Phase 3,Not Applicable
9 Neurotransmitter Agents Phase 4,Not Applicable
10 Anti-Infective Agents Phase 4,Phase 3
11
Histamine Phosphate Phase 4 51-74-1 65513
12 Analgesics, Opioid Phase 4
13 Liver Extracts Phase 4,Not Applicable
14 Analgesics Phase 4
15 Retinol palmitate Phase 4
16 Dermatologic Agents Phase 4
17 Anesthetics, Local Phase 4
18 Autonomic Agents Phase 4
19 Central Nervous System Depressants Phase 4
20 retinol Phase 4
21 Buprenorphine, Naloxone Drug Combination Phase 4
22 Antiemetics Phase 4
23 Peripheral Nervous System Agents Phase 4
24 Narcotics Phase 4
25 Antipruritics Phase 4
26 Anesthetics Phase 4
27 Histamine H1 Antagonists Phase 4
28 Narcotic Antagonists Phase 4
29 Histamine Antagonists Phase 4
30 Hypnotics and Sedatives Phase 4
31 Anti-Allergic Agents Phase 4
32 Pharmaceutical Solutions Phase 4,Not Applicable
33 Antiviral Agents Phase 4
34 N-monoacetylcystine Phase 4
35 Expectorants Phase 4
36 Free Radical Scavengers Phase 4
37 Antioxidants Phase 4
38 Respiratory System Agents Phase 4
39 Protective Agents Phase 4
40 Antidotes Phase 4
41
Lactulose Approved Phase 3,Not Applicable 4618-18-2 11333
42
Rifaximin Approved, Investigational Phase 3 80621-81-4 6436173
43 Anti-Bacterial Agents Phase 3
44 Nucleic Acid Synthesis Inhibitors Phase 3
45 Rifamycins Phase 3
46 rifamycin SV Phase 3
47
gamma-Aminobutyric acid Approved, Investigational Not Applicable 56-12-2 119
48
Caspofungin Approved 179463-17-3, 162808-62-0 468682 2826718
49
Anidulafungin Approved, Investigational 166663-25-8 166548
50
Miconazole Approved, Investigational, Vet_approved 22916-47-8 4189

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 Single Dose Pharmacokinetics of Suboxone Study in Hepatic Impaired Subjects Completed NCT01846455 Phase 4 2.0mg Buprenorphine/0.5mg Naloxone;Promethazine
2 Study of N-Acetylcysteine in Acute Liver Failure (ALF) Terminated NCT00896025 Phase 4 N-acetylcysteine
3 RICE Trial: Rifaximin In Chronic Hepatic Encephalopathy - A Randomized, Controlled Trial Unknown status NCT00364689 Phase 3 Rifaximin alone, Rifaximin combined with Lactulose
4 Evaluation of Mechanisms Responsible for Coma in Patients Affected by Fulminant, Acute and Chronic Hepatic Failure Unknown status NCT01582087
5 Effects Of Gamma Aminobutyric Acid On The Progression Of New Onset Juvenile Type 1 Diabetes Unknown status NCT01781884 Not Applicable Gamma Aminobutyric Acid (GABA);Placebo
6 Efficacy Study of Polyethylene Glycol 3350-electrolyte Solution (GoLYTELY®) Versus Lactulose in Patients With Hepatic Encephalopathy. Completed NCT01283152 Not Applicable Polyethylene glycol 3350-electrolyte solution (GoLYTELY®);Lactulose
7 Risk Of Severe Hepatic Injury In Patients With Invasive Candidiasis Treated With Echinocandins Terminated NCT01213823
8 Factors Associated With End Stage Liver Disease Terminated NCT01846819
9 Hepatic Encephalopathy: Lactulose or Polyethylene Glycol (H.E.L.P.) Withdrawn NCT01923376 Not Applicable Lactulose;Polyethylene Glycol 3350

Search NIH Clinical Center for Hepatic Coma

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: hepatic encephalopathy

Genetic Tests for Hepatic Coma

Anatomical Context for Hepatic Coma

MalaCards organs/tissues related to Hepatic Coma:

41
Liver, Brain, Testes, Small Intestine, Bone, Spleen, Cortex

Publications for Hepatic Coma

Articles related to Hepatic Coma:

(show top 50) (show all 1095)
# Title Authors Year
1
Living Donor Liver Transplantation in Acute Liver Failure Patients with Grade IV Encephalopathy: Is Deep Hepatic Coma Still an Absolute Contraindication? A Successful Single-Center Experience. ( 29531210 )
2018
2
Acute liver failure and hepatic encephalopathy in exertional heat stroke. ( 30061127 )
2018
3
Hepatic encephalopathy: Another brick in the wall. ( 30414737 )
2018
4
Impaired Tactile Temporal Discrimination in Patients With Hepatic Encephalopathy. ( 30425672 )
2018
5
Hepatic Encephalopathy in Patients in Lviv (Ukraine). ( 30425951 )
2018
6
Neuroprotective Effect of Nortriptyline in Overt Hepatic Encephalopathy Through Attenuation of Mitochondrial Dysfunction. ( 30428281 )
2018
7
Long-Term Effect of Rifaximin with and without Lactulose on the Active Bacterial Assemblages in the Proximal Small Bowel and Faeces in Patients with Minimal Hepatic Encephalopathy. ( 30428474 )
2018
8
Clinical Predictors for Poor Quality of Life in Patients With Covert Hepatic Encephalopathy. ( 30439761 )
2018
9
A Mean Field Model of Acute Hepatic Encephalopathy. ( 30440882 )
2018
10
Establishment and evaluation of a model for predicting 3-month mortality in Chinese patients with hepatic encephalopathy. ( 30443767 )
2018
11
Long-term management of hepatic encephalopathy with lactulose and/or rifaximin: a review of the evidence. ( 30444745 )
2018
12
Preliminary experience with single fecal microbiota transplant for treatment of recurrent overt hepatic encephalopathy-A case series. ( 30474827 )
2018
13
Neurocritical Care Management of Hepatic Encephalopathy and Coma in Liver Failure. ( 30485883 )
2018
14
Serum sodium as a risk factor for hepatic encephalopathy in patients with cirrhosis and ascites. ( 30500090 )
2018
15
Protective role of chrysin on thioacetamide-induced hepatic encephalopathy in rats. ( 30500344 )
2018
16
Diagnosis of covert hepatic encephalopathy: a multi-center study testing the utility of single versus combined testing. ( 30506333 )
2018
17
Canadian regulations and legal ramifications for hepatic encephalopathy: a descriptive analysis. ( 30510040 )
2018
18
Altered Topological Properties of Gray Matter Structural Covariance Networks in Minimal Hepatic Encephalopathy. ( 30555305 )
2018
19
Is sarcopenia associated with hepatic encephalopathy in liver cirrhosis? A systematic review and meta-analysis. ( 30279030 )
2018
20
Complications of Cirrhosis in Primary Care: Recognition and Management of Hepatic Encephalopathy. ( 30286824 )
2018
21
Association of proton pump inhibitors with the risk of hepatic encephalopathy during hospitalization for liver cirrhosis. ( 30288280 )
2018
22
Design of the Prospective Real-world Outcomes Study of hepatic encephalopathy Patients' Experience on Rifaximin-α (PROSPER): an observational study among 550 patients. ( 30288327 )
2018
23
Proton pump inhibitors are associated to minimal and overt hepatic encephalopathy and increase mortality in cirrhotics. ( 30289992 )
2018
24
The changes of mitochondria in substantia nigra and anterior cerebral cortex of hepatic encephalopathy induced by thioacetamide. ( 30290401 )
2018
25
Update in Hepatic Encephalopathy. ( 30302035 )
2018
26
L-Ornithine L-Aspartate is Effective and Safe for the Treatment of Hepatic Encephalopathy in Cirrhosis. ( 30302036 )
2018
27
Race and Gradient Difference Are Associated with Increased Risk of Hepatic Encephalopathy Hospital Admission After Transjugular Intrahepatic Portosystemic Shunt Placement. ( 30302042 )
2018
28
Pathogenesis of Hepatic Encephalopathy in Chronic Liver Disease. ( 30302043 )
2018
29
Hyperammonemia in Hepatic Encephalopathy. ( 30302044 )
2018
30
Role of Peripheral Inflammation in Hepatic Encephalopathy. ( 30302045 )
2018
31
Cerebral Blood Flow and Metabolism in Hepatic Encephalopathy-A Meta-Analysis. ( 30302046 )
2018
32
Hepatic Encephalopathy and Astrocyte Senescence. ( 30302047 )
2018
33
Efficacy of l-Ornithine l-Aspartate for the Treatment of Hepatic Encephalopathy and Hyperammonemia in Cirrhosis: Systematic Review and Meta-Analysis of Randomized Controlled Trials. ( 30302048 )
2018
34
Retraction: DA Negatively Regulates IGF-I Actions Implicated in Cognitive Function via Interaction of PSD95 and nNOS in Minimal Hepatic Encephalopathy. ( 30310379 )
2018
35
Editorial: predicting hepatic encephalopathy after TIPSS-is multimodal cerebral MRI the answer? Authors' reply. ( 30318680 )
2018
36
Editorial: predicting hepatic encephalopathy after TIPSS-is multimodal cerebral MRI the answer? ( 30318691 )
2018
37
Detection of Hepatic Encephalopathy on 18F-FDG PET/CT Brain Images in a Patient With Decompensated Liver Cirrhosis. ( 30325817 )
2018
38
A Randomized Controlled Trial Comparing the Efficacy of a Combination of Rifaximin and Lactulose with Lactulose only in the Treatment of Overt Hepatic Encephalopathy. ( 30341842 )
2018
39
Hepatic encephalopathy: Sometimes more portal than hepatic. ( 30345537 )
2018
40
Valproic acid induced acute liver injury resulting in hepatic encephalopathy- a case report and literature review. ( 30356994 )
2018
41
Abernethy malformation: beware in cases of unexplained hepatic encephalopathy in adults-case report and review of the relevant literature. ( 30363163 )
2018
42
L-Carnitine for the Treatment of Overt Hepatic Encephalopathy in Patients with Advanced Liver Cirrhosis. ( 30381621 )
2018
43
Treatment with proton pump inhibitors increases the risk for development of hepatic encephalopathy after implantation of transjugular intrahepatic portosystemic shunt (TIPS). ( 30386611 )
2018
44
Alogliptin abates memory injuries of hepatic encephalopathy induced by acute paracetamol intoxication via switching-off autophagy-related apoptosis. ( 30391466 )
2018
45
Primary Prophylaxis to Prevent the Development of Hepatic Encephalopathy in Cirrhotic Patients with Acute Variceal Bleeding. ( 30079329 )
2018
46
Pathological Features of Mitochondrial Ultrastructure Predict Susceptibility to Post-TIPS Hepatic Encephalopathy. ( 30079331 )
2018
47
Connecting occipital alpha band peak frequency, visual temporal resolution, and occipital GABA levels in healthy participants and hepatic encephalopathy patients. ( 30109194 )
2018
48
Validation of the simplified Animal Naming Test as primary screening tool for the diagnosis of covert hepatic encephalopathy. ( 30131209 )
2018
49
A Head CT is Unnecessary in the Initial Evaluation of A Cirrhotic Patient with Recurrent Hepatic Encephalopathy. ( 30145558 )
2018
50
Olfactory Function is Affected in Patients with Cirrhosis Depending on the Severity of Hepatic Encephalopathy. ( 30145560 )
2018

Variations for Hepatic Coma

Expression for Hepatic Coma

Search GEO for disease gene expression data for Hepatic Coma.

Pathways for Hepatic Coma

Pathways related to Hepatic Coma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.02 ACACA DBI
2 10.6 ALB F2
3
Show member pathways
9.88 DBI TSPO

GO Terms for Hepatic Coma

Cellular components related to Hepatic Coma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 9.35 ALB DBI F2 GPT TSPO
2 endoplasmic reticulum lumen GO:0005788 8.8 ALB DBI F2

Biological processes related to Hepatic Coma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of reactive oxygen species metabolic process GO:2000379 8.62 F2 TSPO

Molecular functions related to Hepatic Coma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 pyridoxal phosphate binding GO:0030170 8.62 ALB GPT

Sources for Hepatic Coma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....